Advertisement

Dermatomyositis

  • Peter B. Chansky
  • Lavanya Mittal
  • Cord Sunderkötter
  • Victoria P. Werth
Chapter

Abstract

Dermatomyositis (DM), in addition to polymyositis (PM) and inclusion body myositis, is categorized as an autoimmune inflammatory myopathy. This group of disorders is characterized by the notable features of symmetric proximal skeletal muscle weakness and laboratory findings consistent with muscle inflammation. DM, unique among the group of inflammatory myopathies, also exhibits a set of distinctive and bothersome cutaneous findings and may present with other systemic symptoms such as interstitial lung disease, arthritis, dysphagia, and an increased risk for internal malignancy. Classic DM presents with skin findings, proximal muscle weakness, and laboratory or radiologic evidence of myositis. When DM occurs in the complete absence of muscular symptoms and muscle inflammation, it is known as amyopathic DM (formally DM sine myositis). The presence of DM-related skin signs with subclinical myopathy and borderline evidence of muscle inflammation is known as hypomyopathic DM [1].

References

  1. 1.
    Bolognia J, Schaffer JV, Duncan KO, et al. Dermatology essentials. Oxford: Saunders/Elsevier; 2014.Google Scholar
  2. 2.
    Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet. 2003;362:971–82.CrossRefPubMedGoogle Scholar
  3. 3.
    Bohan A, Peter JB, Bowman RL, et al. Computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine (Baltimore). 1977;56:255–86.CrossRefGoogle Scholar
  4. 4.
    Jacobson DL, Gange SJ, Rose NR, et al. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol. 1997;84:223–43.CrossRefPubMedGoogle Scholar
  5. 5.
    Marie I, Hatron PY, Levesque H, et al. Influence of age on characteristics of polymyositis and dermatomyositis in adults. Medicine (Baltimore). 1999;78:139–47.CrossRefGoogle Scholar
  6. 6.
    Meyer A, Meyer N, Schaeffer M, et al. Incidence and prevalence of inflammatory myopathies: a systematic review. Rheumatology (Oxford). 2015;54:50–63.CrossRefGoogle Scholar
  7. 7.
    Hengstman GJ, van Venrooij WJ, Vencovsky J, et al. The relative prevalence of dermatomyositis and polymyositis in Europe exhibits a latitudinal gradient. Ann Rheum Dis. 2000;59:141–2.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Bendewald MJ, Wetter DA, Li X, et al. Incidence of dermatomyositis and clinically amyopathic dermatomyositis: a population-based study in Olmsted County, Minnesota. Arch Dermatol. 2010;146:26–30.CrossRefPubMedGoogle Scholar
  9. 9.
    Gerami P, Schope JM, McDonald L, et al. A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis sine myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies. J Am Acad Dermatol. 2006;54:597–613.CrossRefPubMedGoogle Scholar
  10. 10.
    Klein RQ, Teal V, Taylor L, et al. Number, characteristics, and classification of patients with dermatomyositis seen by dermatology and rheumatology departments at a large tertiary medical center. J Am Acad Dermatol. 2007;57:937–43.CrossRefPubMedGoogle Scholar
  11. 11.
    James WD, Elston DM, Berger TG, et al. Andrews’ diseases of the skin: clinical dermatology. 11th ed. London: Saunders Elsevier; 2011.Google Scholar
  12. 12.
    Klein-Weigel PF, Sunderkotter C, Sander O. Nailfold capillaroscopy microscopy - an interdisciplinary appraisal. Vasa. 2016;45:353–64.CrossRefPubMedGoogle Scholar
  13. 13.
    Sander O, Sunderkotter C, Kotter I, et al. Capillaroscopy. Procedure and nomenclature. Z Rheumatol. 2010;69:253–62.CrossRefPubMedGoogle Scholar
  14. 14.
    Wesley NO, Maibach HI. Racial (ethnic) differences in skin properties: the objective data. Am J Clin Dermatol. 2003;4:843–60.CrossRefPubMedGoogle Scholar
  15. 15.
    Weigand DA, Gaylor JR. Irritant reaction in Negro and Caucasian skin. South Med J. 1974;67:548–51.CrossRefPubMedGoogle Scholar
  16. 16.
    Zhao CYHE, Hao EY, Oh DD, et al. A comparison study of clinical-related atopic dermatitis outcome measures for intermediate- to dark-skinned patients. Br J Dermatol. 2017;176:985–92.CrossRefPubMedGoogle Scholar
  17. 17.
    Krathen MS, Fiorentino D, Werth VP. Dermatomyositis. Curr Dir Autoimmun. 2008;10:313–32.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Pfleiderer B, Lange J, Loske KD, et al. Metabolic disturbances during short exercises in dermatomyositis revealed by real-time functional 31P magnetic resonance spectroscopy. Rheumatology (Oxford). 2004;43:696–703.CrossRefGoogle Scholar
  19. 19.
    Targoff IN. Laboratory testing in the diagnosis and management of idiopathic inflammatory myopathies. Rheum Dis Clin N Am. 2002;28:859–90. viiiCrossRefGoogle Scholar
  20. 20.
    Parronchi P, Radice A, Palterer B, et al. MDA5-positive dermatomyositis: an uncommon entity in Europe with variable clinical presentations. Clin Mol Allergy. 2015;13:2.CrossRefGoogle Scholar
  21. 21.
    Murase C, Muro Y, Akiyama M. Rapid increase of serum anti-MDA-5 antibodies and exacerbation of clinically amyopathic dermatomyositis/interstitial lung disease. J Eur Acad Dermatol Venereol. 2017;31:e43–4.CrossRefPubMedGoogle Scholar
  22. 22.
    Fujimoto M, Watanabe R, Ishitsuka Y, et al. Recent advances in dermatomyositis-specific autoantibodies. Curr Opin Rheumatol. 2016;28:636–44.CrossRefPubMedGoogle Scholar
  23. 23.
    Chinoy H, Lamb JA, Ollier WE, et al. An update on the immunogenetics of idiopathic inflammatory myopathies: major histocompatibility complex and beyond. Curr Opin Rheumatol. 2009;21:588–93.CrossRefPubMedGoogle Scholar
  24. 24.
    Niklas K, Niklas AA, Majewski D, et al. Rheumatic diseases induced by drugs and environmental factors: the state-of-the-art - part two. Reumatologia. 2016;54:165–9.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Qiang JK, Kim WB, Baibergenova A, et al. Risk of malignancy in dermatomyositis and polymyositis: a systematic review and meta-analysis. J Cutan Med Surg. 2017;21:131–6.CrossRefPubMedGoogle Scholar
  26. 26.
    Hill CL, Zhang Y, Sigurgeirsson B, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet. 2001;357:96–100.CrossRefPubMedGoogle Scholar
  27. 27.
    Chen YJ, CY W, Huang YL, et al. Cancer risks of dermatomyositis and polymyositis: a nationwide cohort study in Taiwan. Arthritis Res Ther. 2010;12:R70.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Andras C, Ponyi A, Constantin T, et al. Dermatomyositis and polymyositis associated with malignancy: a 21-year retrospective study. J Rheumatol. 2008;35:438–44.PubMedGoogle Scholar
  29. 29.
    Fardet L, Dupuy A, Gain M, et al. Factors associated with underlying malignancy in a retrospective cohort of 121 patients with dermatomyositis. Medicine (Baltimore). 2009;88:91–7.CrossRefGoogle Scholar
  30. 30.
    Rajadhyaksha A, Baheti TG, Mehra S, et al. Dermatomyositis: a rare presentation of HIV seroconversion illness. J Clin Rheumatol. 2012;18:298–300.CrossRefPubMedGoogle Scholar
  31. 31.
    Manie M. Meeting the challenges in the diagnosis of inflammatory myopathies. S Afr Med J. 2015;105:1076.CrossRefPubMedGoogle Scholar
  32. 32.
    Ogoina D, Umar A, Obiako OR. Dermatomyositis associated with HIV-1 infection in a Nigerian adult female: a case report. Afr Health Sci. 2012;12:74–6.PubMedPubMedCentralGoogle Scholar
  33. 33.
    Dauden E, Penas PF, Rios L, et al. Leishmaniasis presenting as a dermatomyositis-like eruption in AIDS. J Am Acad Dermatol. 1996;35:316–9.CrossRefPubMedGoogle Scholar
  34. 34.
    Harland CC, Marsden JR, Vernon SA, et al. Dermatomyositis responding to treatment of associated toxoplasmosis. Br J Dermatol. 1991;125:76–8.CrossRefPubMedGoogle Scholar
  35. 35.
    Lam C, Vleugels RA. Management of cutaneous dermatomyositis. Dermatol Ther. 2012;25:112–34.CrossRefPubMedGoogle Scholar
  36. 36.
    Sunderkotter C, Nast A, Worm M, et al. Guidelines on dermatomyositis--excerpt from the interdisciplinary S2k guidelines on myositis syndromes by the German Society of Neurology. J Dtsch Dermatol Ges. 2016;14:321–38.CrossRefPubMedGoogle Scholar
  37. 37.
    Hollar CB, Jorizzo JL. Topical tacrolimus 0.1% ointment for refractory skin disease in dermatomyositis: a pilot study. J Dermatolog Treat. 2004;15:35–9.CrossRefPubMedGoogle Scholar
  38. 38.
    Woo TY, Callen JP, Voorhees JJ, et al. Cutaneous lesions of dermatomyositis are improved by hydroxychloroquine. J Am Acad Dermatol. 1984;10:592–600.CrossRefPubMedGoogle Scholar
  39. 39.
    Ang GC, Werth VP. Combination antimalarials in the treatment of cutaneous dermatomyositis: a retrospective study. Arch Dermatol. 2005;141:855–9.CrossRefPubMedGoogle Scholar
  40. 40.
    Kasteler JS, Callen JP. Low-dose methotrexate administered weekly is an effective corticosteroid-sparing agent for the treatment of the cutaneous manifestations of dermatomyositis. J Am Acad Dermatol. 1997;36:67–71.CrossRefPubMedGoogle Scholar
  41. 41.
    Dalakas MC, Illa I, Dambrosia JM, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med. 1993;329:1993–2000.CrossRefPubMedGoogle Scholar
  42. 42.
    Edge JC, Outland JD, Dempsey JR, et al. Mycophenolate mofetil as an effective corticosteroid-sparing therapy for recalcitrant dermatomyositis. Arch Dermatol. 2006;142:65–9.CrossRefPubMedGoogle Scholar
  43. 43.
    Oddis CV, Reed AM, Aggarwal R, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum. 2013;65:314–24.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Aggarwal R, Loganathan P, Koontz D, et al. Cutaneous improvement in refractory adult and juvenile dermatomyositis after treatment with rituximab. Rheumatology (Oxford). 2017;56:247–54.CrossRefGoogle Scholar
  45. 45.
    Boswell JS, Costner MI. Leflunomide as adjuvant treatment of dermatomyositis. J Am Acad Dermatol. 2008;58:403–6.CrossRefPubMedGoogle Scholar
  46. 46.
    Sereda D, Werth VP. Improvement in dermatomyositis rash associated with the use of antiestrogen medication. Arch Dermatol. 2006;142:70–2.CrossRefPubMedGoogle Scholar
  47. 47.
    Paller AS. The use of pulse corticosteroid therapy for juvenile dermatomyositis. Pediatr Dermatol. 1996;13:347–8.CrossRefPubMedGoogle Scholar
  48. 48.
    Oliveri MB, Palermo R, Mautalen C, et al. Regression of calcinosis during diltiazem treatment in juvenile dermatomyositis. J Rheumatol. 1996;23:2152–5.PubMedGoogle Scholar
  49. 49.
    Ruperto N, Pistorio A, Oliveira S, et al. Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial. Lancet. 2016;387:671–8.CrossRefPubMedGoogle Scholar
  50. 50.
    Bunch TW. Prednisone and azathioprine for polymyositis: long-term followup. Arthritis Rheum. 1981;24:45–8.CrossRefPubMedGoogle Scholar
  51. 51.
    Newman ED, Scott DW. The use of low-dose oral methotrexate in polymyositis and dermatomyositis. J Clin Rheumatol. 1995;1:99–102.CrossRefPubMedGoogle Scholar
  52. 52.
    Oddis CV. Update on the pharmacological treatment of adult myositis. J Intern Med. 2016;280:63–74.CrossRefPubMedGoogle Scholar
  53. 53.
    Moghadam-Kia S, Aggarwal R, Oddis CV. Treatment of inflammatory myopathy: emerging therapies and therapeutic targets. Expert Rev Clin Immunol. 2015;11:1265–75.CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Oddis CV, Sciurba FC, Elmagd KA, et al. Tacrolimus in refractory polymyositis with interstitial lung disease. Lancet. 1999;353:1762–3.CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Faulds D, Goa KL, Benfield P. Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders. Drugs. 1993;45:953–1040.CrossRefPubMedGoogle Scholar
  56. 56.
    Miller FW, Leitman SF, Cronin ME, et al. Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis. N Engl J Med. 1992;326:1380–4.CrossRefPubMedGoogle Scholar
  57. 57.
    Yosipovitch G, Tan A, LoSicco K, et al. A comparative study of clinical characteristics, work-up, treatment, and association to malignancy in dermatomyositis between two tertiary skin centers in the USA and Singapore. Int J Dermatol. 2013;52:813–9.CrossRefPubMedGoogle Scholar
  58. 58.
    Nakashima R, Hosono Y, Mimori T. Clinical significance and new detection system of autoantibodies in myositis with interstitial lung disease. Lupus. 2016;25:925–33.CrossRefPubMedGoogle Scholar
  59. 59.
    MC L, Lai CL, Tsai CC, et al. Increased risk of pulmonary and extra-pulmonary tuberculosis in patients with rheumatic diseases. Int J Tuberc Lung Dis. 2015;19:1500–6.CrossRefGoogle Scholar
  60. 60.
    PH W, Lin YT, Yang YH, et al. The increased risk of active tuberculosis disease in patients with dermatomyositis - a nationwide retrospective cohort study. Sci Rep. 2015;5:16303.CrossRefGoogle Scholar
  61. 61.
    Kim SH, Park IN. Acute respiratory distress syndrome as the initial clinical manifestation of an antisynthetase syndrome. Tuberc Respir Dis (Seoul). 2016;79:188–92.CrossRefGoogle Scholar
  62. 62.
    Mathai SC, Danoff SK. Management of interstitial lung disease associated with connective tissue disease. BMJ. 2016;352:h6819.CrossRefPubMedGoogle Scholar
  63. 63.
    Marie I, Josse S, Decaux O, et al. Comparison of long-term outcome between anti-Jo1- and anti-PL7/PL12 positive patients with antisynthetase syndrome. Autoimmun Rev. 2012;11:739–45.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Peter B. Chansky
    • 1
    • 2
  • Lavanya Mittal
    • 1
    • 2
  • Cord Sunderkötter
    • 3
    • 4
  • Victoria P. Werth
    • 5
  1. 1.Corporal Michael J. Crescenz Veterans Affairs Medical CenterPhiladelphiaUSA
  2. 2.Department of Dermatology, Perelman School of MedicineUniversity of PennsylvaniaPhiladelphiaUSA
  3. 3.Department of DermatologyMartin-Luther-University of Halle WittenbergHalleGermany
  4. 4.Department of Dermatology and VenerologyUniversitätsklinikum MünsterMünsterGermany
  5. 5.Department of DermatologyPerelman Center for Advanced MedicinePhiladelphiaUSA

Personalised recommendations